In Plain English: The Clinical Takeaway
- Real-Time Observation: SphynxVision lets researchers watch biological changes and drug delivery as they happen, rather than relying on before-and-after snapshots.
- Standard Room Lighting: Unlike traditional systems that require closed, dark chambers, this technology operates under normal lighting conditions to simplify active surgeries and injections.
- Enhanced Precision: A 100-times brighter light source and specialized image processing reduce movement blur and reveal tiny structures like tiny blood vessels and small cancer cell clusters.
Engineering a Bench-Side Window Into Living Systems
Fluorescence imaging remains a cornerstone of early-stage laboratory research, allowing scientists to track targeted cells, molecules, and therapeutic agents by attaching fluorescent labels that light up under specific illumination. However, conventional imaging systems face a persistent physical hurdle: ordinary room light can drown out these faint signals. To counter this interference, standard laboratory setups require researchers to place experimental subjects inside closed, dark chambers.
That barrier restricts what scientists can observe during active procedures. While this approach yields snapshots of what happened before and after, it can leave out what happened in between.
SphynxVision, engineered by the MUSC startup OncoBLAZE, bypasses this limitation through an open, bench-side architecture. Dieter Haemmerich, Ph.D., a researcher at the MUSC Hollings Cancer Center and CEO of OncoBLAZE, explained the design philosophy in project documentation: “SphynxVision was built around the experiment, not around the imaging chamber. Researchers often need to see what is happening while they perform surgeries or treat subjects. Our system makes that possible in a flexible, bench-side system.”
Proprietary Illumination and Real-Time Tracking Mechanisms
The technical capability of SphynxVision relies on a dual-pronged approach combining extreme illumination with advanced software filtering. The system utilizes a proprietary light source about 100 times brighter than those found in conventional preclinical imaging hardware, generating a much stronger fluorescence signal that cuts through ambient interference. Simultaneously, specialized image-processing algorithms filter out remaining interference from room light.
This hardware-software integration permits rapid image capture rates of multiple images per second. In preclinical evaluations, this velocity reduces the blurring that movement can cause and lets investigators track biological changes in real time. For instance, when evaluating a cancer drug, researchers can directly observe the compound’s transit through the body as it is delivered, noting where it goes, when it arrives, and how its distribution changes over time.
Such speed proves critical when changes happen within seconds. Hollings head and neck cancer surgeon Dauren Adilbay, M.D., Ph.D., has utilized SphynxVision in preclinical studies to develop and test a new fluorescent contrast agent.
From Laboratory Necessity to Commercial Launch
The creation of SphynxVision stemmed initially from upwards of ten years of investigation at MUSC and Hollings centered on administering chemotherapy more accurately to tumors while restricting systemic exposure throughout the rest of the organism. Achieving that level of precision required a direct view of therapeutic agents moving through living systems during delivery.
“There wasn’t a system able to do that,” Haemmerich noted regarding the origin of the device. “That’s why we developed this.” Grasping that an open-chamber instrument with intense illumination possessed wider applications, the group deduced that this identical fluorescence technique could supply alternative researchers with a novel mechanism for monitoring ongoing experiments.
In September, OncoBLAZE intends to introduce SphynxVision to attendees at the World Molecular Imaging Congress taking place in Salt Lake City, which represents a crucial milestone in introducing the enterprise’s initial marketable commodity. Concurrently with this debut, the enterprise looks forward to engaging a select cohort of laboratories for their Pioneer Program, providing them access to trial a preliminary model and supply evaluations prior to a wider commercial release.
| Feature | Conventional Imaging Systems | SphynxVision (OncoBLAZE) |
|---|---|---|
| Environmental Lighting | Requires closed, dark chambers | Operates under normal room lighting |
| Illumination Intensity | Standard baseline output | ~100x brighter proprietary light source |
| Temporal Resolution | Intermittent snapshots (before/after) | Real-time capture at multiple images per second |
| Surgical Integration | Restricted by chamber geometry | Open, bench-side flexibility for active procedures |
Contraindications & When to Consult a Doctor
Because SphynxVision is designed for early-stage research conducted before a treatment or technology is ready to be tested in patients, it possesses no direct clinical contraindications for human patients.
